Cardiomyopathy in Fabry disease

Article written and reviewed by Dr Luca Moretti

Fabry disease is an X-linked lysosomal disorder caused by pathogenic variants in GLA, the gene encoding alpha-galactosidase A. Reduced enzyme activity impairs degradation of glycosphingolipids, especially globotriaosylceramide and globotriaosylsphingosine, which accumulate in cardiomyocytes, endothelial cells, kidney and nervous system. In the heart this does more than produce storage: it activates hypertrophy, inflammation, microvascular disease and ultimately fibrosis. Fabry cardiomyopathy is therefore a progressive biological process, not simply a thick wall.

The classic phenotype often begins in childhood or adolescence with neuropathic pain, hypohidrosis, heat and exercise intolerance, angiokeratomas and gastrointestinal symptoms; renal, cerebrovascular and cardiac damage emerges over time. Late-onset variants may predominantly involve the heart or kidney and present in adulthood as unexplained hypertrophy. In women, mosaicism from X inactivation generates a continuum from no signs to severe disease. X-linked variability makes it unacceptable to regard them as simple carriers.

Recognizing Fabry disease changes management because specific therapies exist and because each diagnosis opens an entire family to screening. At the same time, increasing use of panels has revealed variants of uncertain significance and variably penetrant alleles that should not be medicalized without evidence. The goal is not to assign every hypertrophy to a genetic result, but to demonstrate gene-phenotype coherence supported by sex, biochemistry, organs, imaging and segregation.

From lysosome to myocardial fibrosis

Gb3 and lyso-Gb3 begin to accumulate long before symptoms. The volume of storage contributes to increased mass, but is not sufficient to explain the extent of hypertrophy: trophic signals, oxidative stress, altered energy metabolism and inflammation amplify the cardiomyocyte response. Endothelial and vascular smooth-muscle cells are also involved, with microcirculatory dysfunction. The storage phase may have abnormal ECG or mapping when wall thickness and global function still appear normal.

With progression, cellular injury and local inflammation precede replacement fibrosis, often in the basal inferolateral wall. Scar becomes an arrhythmic substrate and limits response to substrate-reducing therapies. In women, fibrosis may appear even with modest hypertrophy, probably because of a mosaic of affected and spared cardiomyocytes; in classically affected men, hypertrophy and systemic burden tend to occur earlier. The fibrotic transition is the point beyond which cardiac reversibility decreases.

The microcirculation may be dysfunctional without epicardial coronary stenoses, causing angina, reduced flow reserve and chronically elevated troponin. Conduction-system involvement evolves: in early stages atrioventricular conduction may accelerate and shorten the PR; later, storage and fibrosis cause sinus-node dysfunction and block. Pan-cardiac disease links myocardium, microvessels, atria and conduction.

Clinical phenotype and red flags

The most common morphology is concentric left ventricular hypertrophy with preserved systolic function in early stages. Septal asymmetry, right ventricular involvement and, rarely, dynamic obstruction are possible; papillary muscles may be prominent. Dyspnea, reduced exercise capacity, palpitations, angina and syncope are nonspecific, but their association with nephropathy or neurologic signs increases probability. The hypertrophic phenotype should be interpreted as a gateway, not as the final diagnosis.

Acroparesthesias and pain crises triggered by fever, heat or exercise, hypohidrosis, angiokeratomas and cornea verticillata are classic red flags. Proteinuria, reduced filtration, hearing loss, vertigo and cerebrovascular events complete the spectrum. No sign is mandatory in late-onset variants; a man over forty with unexplained hypertrophy, renal disease or conduction abnormalities still deserves assessment. The multisystem constellation is more useful than searching for a single pathognomonic finding.

The differential diagnosis includes hypertension, aortic stenosis, sarcomeric cardiomyopathy, amyloidosis, PRKAG2, Danon and mitochondrial disease. Hypertension and Fabry can coexist; a common cause does not exclude the rare one when thickness, age and extracardiac signs remain disproportionate. Dual pathology is particularly important in older adults, in whom ATTR and gammopathies can confound imaging and biomarkers.

ECG, rhythm and arrhythmic risk

The ECG may show a short PR, high-voltage QRS complexes, repolarization abnormalities and hypertrophy criteria before the patient reports symptoms. The short PR often results from accelerated atrioventricular conduction rather than an accessory pathway; therefore, an automatic diagnosis of Wolff-Parkinson-White can lead to unnecessary procedures. With age, PR and QRS lengthen and blocks appear. The electrocardiographic sequence reflects progression of storage and fibrosis.

Atrial fibrillation, flutter, supraventricular tachycardias, bradycardia and block are common in advanced stages. Nonsustained ventricular tachycardia and sudden death are associated with hypertrophy, fibrosis and dysfunction, but there is no Fabry risk calculator validated to the same extent as in other cardiomyopathies. Periodic Holter monitoring and longer monitoring are selected according to symptoms, LGE and previous findings. Individual risk cannot be derived from maximal wall thickness alone.

Atrial fibrillation increases embolic risk in a setting already predisposed to cerebrovascular disease. The threshold for anticoagulation is generally low and common scores may underestimate disease-specific aspects; renal function and cerebral microbleeds influence the choice. Pacemakers and ICDs follow integrated clinical indications, considering block, syncope, tachycardias, fibrosis and expected course. Embolic-arrhythmic prevention remains necessary even during specific therapy.

Echocardiography and magnetic resonance

Echocardiography quantifies mass, wall thickness, atria, diastolic function, right ventricle, valves and strain. Reduced regional longitudinal strain, particularly inferolaterally, may precede a fall in ejection fraction; however, no pattern is specific enough to confirm Fabry disease. Increasing mass and diastolic dysfunction are followed serially to measure progression or response. Echocardiographic phenotyping gains value when the same method is used over time.

CMR is particularly informative. Lipid storage often lowers global native T1 before scar forms; in inflammatory-fibrotic stages, T1 in the inferolateral wall may pseudonormalize or increase. The finding should be compared with scanner-specific normal values and with other causes of low T1, especially iron. A normal T1 does not exclude Fabry disease, particularly in women or at an early stage. Contextualized T1 is a tissue biomarker, not a standalone diagnostic test.

Mid-wall inferolateral LGE is characteristic of advanced disease and is associated with risk and reduced reversibility. Elevated T2 in the same region and persistent troponin support chronic inflammatory activity, but there is not yet a dedicated standard anti-inflammatory therapy. Extracellular volume may appear normal or globally reduced before scarring because storage is intracellular. The multiparametric map distinguishes storage, inflammation and fibrotic replacement.

Biochemical and genetic confirmation

In men, markedly reduced alpha-galactosidase A activity in leukocytes or another validated sample is a strong clue, to be confirmed by GLA analysis. In women, activity may fall within the normal range because of mosaicism and cannot be used to exclude disease: genetic testing is necessary. Dried blood spot tests are effective for screening, but an abnormal result requires confirmation. The sex-specific strategy is a fundamental diagnostic principle.

Lyso-Gb3 is often very high in men with the classic phenotype and helps distinguish severe variants, whereas it may be only slightly elevated in women or late-onset forms. It does not replace variant classification and there is no universal threshold that by itself defines disease or response. Analysis for deletions, duplications and variants not detected by standard sequencing is added when suspicion remains high. Molecular convergence requires concordant gene, enzyme, biomarker and organ findings.

A variant of uncertain significance does not prove Fabry disease and should not be used for predictive cascade testing or therapy. Population frequency, functional data, specialist databases, phenotype, lyso-Gb3 and segregation are reassessed. Some variants previously considered pathogenic have been reclassified, while others have organ-specific penetrance. Periodic review of the report is part of care in a disease with evolving knowledge.

Specific therapy and timing

Enzyme replacement therapy uses agalsidase alfa or agalsidase beta according to indications and national availability. The enzyme is internalized through mannose-6-phosphate receptors and reduces substrate, with more convincing effects when started before advanced hypertrophy and fibrosis. Regular infusions, reactions and neutralizing antibodies, especially in classically affected men without residual activity, must be monitored. Early therapy aims to prevent damage rather than wait for an irreversible manifestation.

Migalastat is an oral chaperone that stabilizes certain mutant forms of the enzyme and facilitates lysosomal trafficking. It can be prescribed only if the variant is classified as amenable in a validated assay and renal function and regulatory indications are compatible. Oral convenience does not make the drug appropriate for every variant; adherence and organ response must be verified. Molecular amenability is a therapeutic requirement, not a preference.

The choice between enzyme and chaperone considers variant, phenotype, kidney function, evidence, tolerance, wishes and access. Pegunigalsidase alfa and other platforms may be available in specific regulatory settings; substrate reduction and gene therapy are areas of research, not equivalents of established standard care for every patient. Success is not measured only with lyso-Gb3: mass, function, LGE, kidney, pain and events require a multiorgan response.

Cardiology treatment and renal protection

Common cardiovascular factors are treated rigorously. ACE inhibitors or ARBs are important in proteinuria if tolerated; modern nephroprotective strategies are assessed with the nephrologist according to filtration and available evidence. In heart failure with reduced ejection fraction, guideline-directed therapy is applied, adapted to bradycardia, block and renal function. Diuretics control congestion without excessive preload reduction. Cardiorenal protection is inseparable from substrate-reduction therapy.

Angina without stenosis is managed after excluding coronary disease and considering microvascular disease; beta-blockers or other drugs may be limited by conduction abnormalities. Significant dynamic obstruction is rare and requires an expert-center approach, avoiding attribution of every gradient to Fabry disease. Valve disease is generally mild, but age and calcification retain standard indications. Phenotype-directed therapy should solve the present problem without assuming that enzyme therapy will correct it rapidly.

A pacemaker is indicated for bradycardia or block according to standard criteria; secondary-prevention ICD indication is clear, whereas primary prevention requires judgment regarding LGE, hypertrophy, dysfunction, tachycardia and syncope. A high pacing burden in an impaired ventricle may favor physiologic pacing systems or resynchronization. Device planning anticipates conduction progression and reduces repeated procedures.

Clinical staging and progression

A pre-hypertrophic phase may show an abnormal ECG, reduced strain, low T1 or altered biomarkers without increased mass. This is followed by a storage and hypertrophy phase, then an inflammatory-fibrotic period in which LGE and troponin become evident; finally scar, atrial dilation, arrhythmias and dysfunction dominate. These phases overlap and do not constitute a formally universal scale. Biological staging helps explain why two patients with the same thickness may have different response and risk.

Natriuretic peptides reflect pressures and atrial involvement, while persistent troponin is associated with injury, but renal function and rhythm confound both. Lyso-Gb3 mainly describes systemic burden and biochemical response, does not replace LGE and by itself does not predict an event. Mass, T1, T2, ECV and strain provide complementary domains. The multiparametric profile is more robust than classification based on the most striking marker.

Endomyocardial biopsy shows vacuoles with lamellar inclusions, but similar findings may occur with cationic amphiphilic drugs such as amiodarone or hydroxychloroquine. Electron microscopy alone does not prove a GLA variant and absence of zebra bodies in a limited sample does not exclude every stage. Ultrastructural diagnosis requires medication history, enzyme testing and genetics to avoid confusing acquired phospholipidosis with Fabry disease.

Kidney, brain and vascular risk

Albuminuria may precede reduced filtration and signals podocyte, endothelial and tubular injury. Estimated renal function affects the dose or choice of some therapies, gadolinium use and anticoagulation. Renal biopsy is useful in selected cases, especially when diabetes, hypertension or an uncertain variant makes etiology ambiguous. Early nephropathy strengthens the diagnosis and offers a protection target before irreversible failure.

Cerebrovascular events depend on small- and large-vessel arteriopathy, hypertension, kidney disease and cardioembolism. White-matter lesions are frequent but nonspecific; vertebrobasilar dolichoectasia may support suspicion. Prevention treats blood pressure, smoking, lipids, diabetes and fibrillation without assuming that enzyme therapy abolishes all risk. Cerebrocardiac prevention links neurology and rhythm management, especially when stroke precedes diagnosis of fibrillation.

Neuropathic pain and dysautonomia may limit activity and tolerance of cardiovascular drugs. Hypohidrosis increases risk during heat and exercise; gastrointestinal symptoms alter hydration and absorption. Low blood pressure may reflect constitution, autonomic neuropathy, excessive therapy or low output and should not automatically be interpreted as good control. Systemic physiology explains why a standard dose produces different effects in Fabry disease.

Response to therapy and antibodies

Enzyme replacement therapy clears substrate mainly in accessible compartments and response varies among endothelium, kidney and cardiomyocyte. Mass reduction may occur, but established LGE tends to persist and progression may continue in advanced stages. Assessment uses the slope over time rather than waiting for normalization. Clinical stabilization can be a meaningful outcome in a disease that would otherwise have continued to accumulate damage.

Men with the classic phenotype and no endogenous enzyme may develop neutralizing anti-drug antibodies, affecting lyso-Gb3 and substrate. Titers, neutralizing capacity, dose and organ response should be interpreted by expert centers; a positive test does not automatically require discontinuation or switching. Immunogenicity is generally different in women and late-onset forms. Immunopharmacologic interpretation separates antibody presence from demonstrated clinical impact.

Switching between products or to migalastat requires a new baseline and an explicit reason, such as tolerance, logistics or variant suitability. Fluctuations in lyso-Gb3 immediately after a switch should not be confused with a cardiac event, and oral adherence must be checked. Mass and function change slowly. Assessment of switching defines the window, measurements and criteria in advance to avoid conclusions based on biologically impossible timing.

Special situations and quality of care

During pregnancy, kidney disease, hypertrophy, arrhythmias and a history of stroke require preconception counseling and a cardio-obstetric team. Data on continuing specific therapies are limited and the decision depends on the product, severity and regulatory setting. Blood pressure, proteinuria, volume and rhythm are monitored more closely. Maternal planning distinguishes X-linked genetic risk from the pregnant woman's clinical risk.

Anesthesia considers hypertrophy, conduction, kidney function, dysautonomia and airway issues, without a general contraindication. A recent ECG and availability of pacing are important in advanced block; fasting and fluids are adapted to kidney and heart function. Contrast, nephrotoxic drugs and renal dosing require review. Procedural safety derives from a shared concise summary, not from leaving a rare-disease label without operational instructions.

Kidney transplantation is possible and corrects renal failure but not disease in other organs; enzyme produced by the transplanted kidney is not sufficient systemic therapy. Heart transplantation may be considered in selected end-stage cases after assessing kidney and brain. Organ selection must establish which component limits survival and which will continue to progress after replacement.

Care includes pain, sleep, activity, fertility, work and mental health. Fortnightly infusions or oral therapy affect life for decades, and adherence depends on organization and understanding, not only willpower. A coordinator reduces duplication among specialists. Therapeutic quality is also measured by the ability to maintain complex care without turning every day into a clinic visit.

Registries have improved knowledge but include selection, different treatments and variable definitions. Indirect comparisons among products do not replace trials or well-controlled studies. Rare events and slow progression require standardized endpoints and long follow-up. Comparative caution is essential when a biomarker reduction is presented as clinical superiority without evidence on events or function.

Follow-up, family and prognosis

Monitoring includes symptoms, blood pressure, ECG, echocardiography, Holter, renal function, albuminuria, lyso-Gb3 and CMR at adapted intervals. Neurology, audiology, ophthalmology and pain assessment complete the map. In treated patients, stability and trajectory are sought rather than immediate normalization of every parameter; established LGE may progress despite substrate reduction. Longitudinal follow-up distinguishes an analytical variation from a biological event.

Once a pathogenic variant has been identified, cascade screening follows X-linked inheritance. All daughters of an affected man inherit the variant and none of his sons do; a heterozygous woman has a 50% chance in each pregnancy of transmitting it, regardless of sex. These rules do not predict severity in daughters. Family counseling integrates genetic risk, the possibility of early diagnosis and reproductive options.

Prognosis is determined by kidney, heart and brain. Fibrosis, hypertrophy, arrhythmias, reduced filtration and proteinuria define higher risk; starting therapy before established damage improves the probability of protection. The disease does not disappear after a single infusion nor become inevitably terminal after diagnosis. A stage-based prognosis allows realistic communication of benefit, residual risk and the importance of treatment continuity.

A suspicion generated through screening should not be presented as a definitive diagnosis before confirmation. This is particularly important for variably penetrant alleles found in hypertrophy or stroke programs: a person may carry a variant without it certainly explaining the phenotype. Communication of the result distinguishes pathogenicity, penetrance and organ causality, three different questions that are often improperly merged.

Pain therapies include neuropathic agents, behavioral strategies and trigger prevention, with renal adjustment. Anti-inflammatory drugs and chronic opioids do not correct the mechanism and may harm kidney or function. Pain control improves sleep and activity, also influencing perceived cardiac capacity. Symptomatic care does not compete with enzyme therapy but completes its functional objective.

In older adults, ATTR, aortic stenosis, hypertension and coronary disease can coexist with Fabry disease. New progression after years of stability is not automatically attributed to the lysosome; nuclear medicine, monoclonal or coronary testing is requested according to probability. Etiologic reassessment prevents a known rare diagnosis from making a second common and treatable disease invisible.

A written plan should state specific therapy, variant, migalastat amenability, kidney function, arrhythmias, device and contacts. In an emergency it avoids inappropriate discontinuation of treatment or use of contrast without assessment. Information continuity is essential when a multisystem patient encounters specialists who rarely see Fabry disease and must make rapid decisions.

Annual pathway review verifies that indication, dose, weight, intervals, renal function and monitoring are coherent and that no organ has been lost between specialists. A simple clinical audit can identify missed infusions, overdue Holter monitoring or increasing proteinuria before they become irreversible events.